Intellectual Property
Aug. 18, 2012
Altered genes can be patented, Federal Circuit rules
In a closely watched decision, a federal appellate court ruled Thursday that biotechology company Myriad Genetics Inc.'s development of altered genes to help fight breast and ovarian cancer can be patented.
Daily Journal Staff Writer
A federal appellate court ruled Thursday that biotechology company Myriad Genetics Inc.'s development of altered genes to help fight breast and ovarian cancer can be patented.
In a 2-1 decision, the U.S. Court of Appeals for the Federal Circuit ruled that because Myriad's altered genes do not exist in nature, they are patent-eligible. The Association for Molecular Pathology v. U.S. Patent a...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In